Skip to main content
Canna~Fangled Abstracts

Enhancement of cannabidiol oral bioavailability through the development of nanostructured lipid carriers: In vitro and in vivo evaluation studies

By December 30, 2024January 6th, 2025No Comments

. 2024 Dec 30.

doi: 10.1007/s13346-024-01766-9.

Online ahead of print.
Iman E Taha 1, Mahmoud A ElSohly 1 2, Mohamed M Radwan 2, Rasha M Elkanayati 1, Amira Wanas 2, Poorva H Joshi 1, Eman A Ashour 3
Affiliations 

Abstract

Cannabidiol (CBD) is a natural product isolated from the Cannabis sativa plant that was approved by the United States Food and Drug Administration (US FDA) for the treatment of resistant epilepsy. Despite its therapeutic potential, CBD’s clinical application is limited by its poor aqueous solubility and low oral bioavailability. The primary aim of this research was to enhance the aqueous solubility and oral bioavailability of CBD by developing nanostructured lipid carriers (NLCs) using conventional hot homogenization method (CHH). In the current study, nine CBD NLC formulations were developed through CHH, of which, NLC5 emerged as the most promising formulation, exhibiting high CBD entrapment efficiency (99.23%), particle size of 207 nm, a polydispersity index of 0.19, and a zeta potential of -26 mV. Additionally, drug release testing for NLC5 showed a high CBD release rate of more than 90% within 15 min, indicating an enhancement of CBD dissolving rate compared to pure CBD. The in vivo pharmacokinetic study of NLC5 formulation showed 27% CBD oral bioavailability. Furthermore, Stability studies conducted at 4 °C and 25 °C on this formulation over three months, revealed consistent parameters, underscoring the robustness of the formulation. In conclusion, the successful formulation of CBD-loaded NLCs resulted in improved CBD release rate, enhanced oral bioavailability of CBD, and maintained stability, making it a promising approach for the effective delivery of CBD.

Keywords: Cannabidiol (CBD), Hot Homogenization, In Vitro and In Vivo Evaluation, Nanostructured Lipid Carrier (NLC), Oral Bioavailability

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: All the animal studies were carried out under the guidelines of Institutional Animal Care and Use Committee (IACUC) of the University of Mississippi under protocol number 22-003. Competing interests: The authors have no relevant financial or non-financial interests to disclose.

References

    1. Radwan MM, Chandra S, Gul S, Elsohly MA. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules. 2020. https://doi.org/10.3390/molecules26092774 . – DOI – PubMed – PMC
    1. Niesink RJM, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry. 2013. https://doi.org/10.3389/fpsyt.2013.00130 . – DOI – PubMed – PMC
    1. Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018. https://doi.org/10.3390/molecules23102478 . – DOI – PubMed – PMC
    1. Todorova J, Lazarov LI, Petrova M, Tzintzarov A, Ugrinova I. The antitumor activity of cannabidiol on lung cancer cell lines A549 and H1299: the role of apoptosis. Biotechnol Biotechnol Equip. 2021. https://doi.org/10.1080/13102818.2021.1915870 . – DOI
    1. Watzl B, Scuderi P, Watson RR. Marijuana Components Stimulate Human Peripheral Blood Mononuclear Cell Secretion of Interferon-Gamma and Supress Interleukin-1 Alpha In Vitro. Int J Immunopharmacol. 1991. https://doi.org/10.1016/0192-0561(91)90160-9 . – DOI – PubMed

LinkOut – more resources

Leave a Reply